Hepatology Highlights
Clara Tow, Robert S. Brown, Zaid Husni Tafesh, Robert E. Schwartz, Russell Rosenblatt, Shawn L. Shah, Nicole T. Shen, Aleksey Novikov, Shirley Cohen‐Mekelburg, Nicholas Russo, Vikas Gupta – 20 November 2017
Memory T cells are significantly increased in rejected liver allografts of rhesus monkeys
Hwajung Kim, Hyeyoung Kim, Sun‐Kyung Lee, Xue‐Li Jin, Tae Jin Kim, Chanho Park, Jae‐Il Lee, Hyo‐Sin Kim, Suk Kyun Hong, Kyung Chul Yoon, Sung Woo Ahn, Kyoung‐Bun Lee, Nam‐Joon Yi, Jaeseok Yang, Kwang‐Woong Lee, Wayne J. Hawthorne, Kyung‐Suk Suh – 18 November 2017 – The rhesus monkey (RM) is an excellent preclinical model in kidney, heart, and islet transplantation that has provided the basis for new immunosuppressive protocols for clinical studies. However, there remain relatively few liver transplantation (LT) models in nonhuman primates.
Novel intraoperative management in the model for end‐stage liver disease–sodium era: Continuous venovenous hemofiltration for severe hyponatremia in liver transplantation
Shunji Nagai, Dilip Moonka, Anita Patel – 17 November 2017
Transferrin as a predictor of survival in cirrhosis
André Viveiros, Armin Finkenstedt, Benedikt Schaefer, Mattias Mandorfer, Bernhard Scheiner, Konrad Lehner, Moritz Tobiasch, Thomas Reiberger, Herbert Tilg, Michael Edlinger, Heinz Zoller – 17 November 2017 – Patients with cirrhosis frequently present with high serum ferritin and low transferrin concentrations, reflecting impaired liver function and inflammation. Recent studies have shown that transferrin and its saturation with iron are Model for End‐Stage Liver Disease–independent predictors of mortality in patients with acute‐on‐chronic liver failure or decompensated cirrhosis.
High mobility group protein B1 controls liver cancer initiation through yes‐associated protein ‐dependent aerobic glycolysis
Ruochan Chen, Shan Zhu, Xue‐Gong Fan, Haichao Wang, Michael T. Lotze, Herbert J. Zeh, Timothy R. Billiar, Rui Kang, Daolin Tang – 17 November 2017 – Emerging studies have suggested that the Hippo pathway is involved in the tumorigenesis of hepatocellular carcinoma (HCC). However, the key regulator of the Hippo pathway in liver tumor metabolic reprogramming remains elusive. Here, we provide evidence that high mobility group box 1 (HMGB1), a chromosomal protein, plays a role in the regulation of the Hippo pathway during liver tumorigenesis.
Ex vivo reduction of thickness in the left lateral section to tailor the graft size in infantile split deceased donor liver transplantation
Seisuke Sakamoto, Kengo Sasaki, Hajime Uchida, Toshihiro Kitajima, Soichi Narumoto, Yoshihiro Hirata, Tomoro Hishiki, Akinari Fukuda, Mureo Kasahara – 16 November 2017
Exercise alters the hepatic immunophenotype to protect against inflammatory liver disease
Abhishek Chauhan, David H. Adams – 16 November 2017
Higher retransplantation rate following extended right split‐liver transplantation: An analysis from the eurotransplant liver follow‐up registry
Joachim Andrassy, Sebastian Wolf, Michael Lauseker, Martin Angele, Marieke D. van Rosmalen, Undine Samuel, Xavier Rogiers, Jens Werner, Markus Guba, for the Eurotransplant Liver Advisory Committee – 16 November 2017 – Split‐liver transplantation has been perceived as an important strategy to increase the supply of liver grafts by creating 2 transplants from 1 allograft. The Eurotransplant Liver Allocation System (ELAS) envisages that the extended right lobes (ERLs) after splitting (usually in the pediatric center) are almost exclusively shipped to a second center.
“CHOP”ing intestinal stem cells on way to cholestatic liver injury
Akanksha Sharma, Chandrashekhar R. Gandhi – 16 November 2017
Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)
Josep M. Llovet, Mihai Pavel, Jordi Rimola, Maria Alba Diaz, Jordi Colmenero, David Saavedra-Perez, Constantino Fondevila, Carmen Ayuso, Josep Fuster, Pere Ginès, Jordi Bruix, Juan Carlos Garcia-Valdecasas – 15 November 2017 – A subset of patients with hepatocellular carcinoma (HCC) beyond Milan criteria might obtain acceptable survival outcomes after liver transplantation. Living donor liver transplantation (LDLT) has emerged as a feasible alternative to overcome the paucity of donors.